Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
AbbVie spent billions of dollars to acquire a potential cancer drug known as Rova-T, but the drug is looking more and more like a bad investment, Business Insider reports.
Details: AbbVie has stopped enrolling new patients in a Phase 3 clinical trial for Rova-T, which an outside monitoring committee had recommended. The drug was intended to treat advanced lung cancer. But in the clinical trial, patients taking Rova-T were dying sooner than patients treated with standard chemotherapy, per BI.